Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?

Joline S. W. Lind, Martijn R. Meijerink*, Anne-Marie C. Dingemans, Cornelis van Kuijk, Michel C. Ollers, Dirk de Ruysscher, Pieter E. Postmus, Egbert F. Smit

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

71 Citations (Web of Science)

Abstract

We investigated the feasibility of serial dynamic contrast-enhanced computed tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving anti-angiogenic (sorafenib) and anti-EGFR (erlotinib) treatment, and correlated tumour blood flow (BF) with treatment outcome. DCE-CTs were performed at baseline and 3 and 6 weeks after starting treatment. Tumour BF, calculated with the maximum slope method, and percentage change were measured in 23 patients (14 male; median age 59 years). Tumour BF was compared at baseline and weeks 3 and 6; the relation with RECIST/Crabb response and progression-free survival (PFS) was assessed. Mean tumour perfusion decreased from 39.2 ml/100 g/min at baseline to 15.1 ml/100 g/min at week 3 (p <0.001) and 9.4 ml/100 g/min at week 6 (p <0.001). Tumour perfusion was lower in RECIST and Crabb responders versus non-responders at week 3 (4.2 versus 17.7 ml/100 g/min, p = 0.03) and week 6 (0 versus 13.4 ml/100 g/min, p = 0.04). Patients with a decrease larger than the median at week 6 tended to have a longer PFS (7.1 versus 5.7 months, p = 0.06). Serial DCE-CTs are feasible in patients with NSCLC and demonstrated a significant decrease in tumour BF following sorafenib/erlotinib therapy. Early changes in tumour BF correlated with objective response and showed a trend towards longer PFS.
Original languageEnglish
Pages (from-to)2890-2898
JournalEuropean Radiology
Volume20
Issue number12
DOIs
Publication statusPublished - Dec 2010

Keywords

  • Dynamic contrast-enhanced CT
  • Erlotinib
  • Sorafenib
  • Non-small cell lung cancer
  • Tumour perfusion

Cite this